Hi there
Thanks for noticing.
Here you go:
link.springer.com/article/10.1...
www.jcvaonline.com/article/S105...
Posts by Kaspar Bachmann
Problem is twofold: LoA are around +/- 10%. ScvO2 of 55 then is not helpful. Trends do not point in the same direction. We showed this here: pubmed.ncbi.nlm.nih.gov/36511508/
And other studies:
doi.org/10.1007/s00134…
doi.org/10.1053/j.jvca���
Bottom line: when it counts, it is not helpful.
IAP measurement does not require seadtion or neuromuscular blockade. That is a myth that needs to disappear. Measuring pressure is simple and accurate; a measurement of 18 is what it is. Sedation and paralytics can lower that number, but that is a therapy for IAP rather than enabling a measurement.
My issue with ScvO2 is, that it can be high while true mixed venous (SvO2) is low. It is a bad surrogate for SvO2.
So when in doubt, float a PAC and know for sure.
LEVOECMO RCT: early administration of levosimendan to facilitate weaning from VA #ECMO in severe but potentially reversible cardiogenic shock
🔍 205 adults/11 ICUs in 🇫🇷
⚖️ early levosimendan administration did not significantly shorten the time to successful weaning of #ECLS at day 30
🔗 bit.ly/4iAwGwT
Thanks for sharing our review! Monitoring GI function when initiating / stepping up nutrition is key to prevent harm from too aggressive nutrition.
My question is, does it truly matter? If there’s a strong signal, shouldn’t I be able to detect it using either method (and vice versa)? And if the signal is borderline, shouldn’t I arrive at the same interpretation if my application and understanding of the statistics used are accurate?
New 📝
We know RV dysfunction occurs on VV-ECMO in ARDS despite ECMO mitigating many of the traditional RV dysfunction risk factors (hypercapnia etc)
We don’t understand RV function dynamically over time on ECMO…
@gurujosh.bsky.social presents the results of the MSSA domain of the SNAP 🫰 trial at #ESCMID2025
fluclox caused more acute kidney injury than cefazolin; early mortality favored cefazolin
Absolutely Herculean effort by the entire global trial team and practice changing data #teamcefazolin
Have you ever wondered what it takes before a clinical trial ends up in your timeline?
Well… we recently published the DDx-BRO trial ⬇️
Here is a 🧵 of its lifecycle: from 💡to 🏁, well, if the latter actually exists.
Core outcome set of daily monitoring of gastrointestinal function in adult critically ill patients: a modified Delphi consensus process (COSMOGI)
Thanks to @criticalcarereviews.com
ccforum.biomedcentral.com/articles/10....
I don’t think that offering specific therapies out of the context of goals of care is helpful and may negatively impact the discussion and patient trajectory.
I think we want to define where a patient wants to be in 1/3/6/12 months and with what level of quality of life. We as a team can then offer specific therapies (i.e. Trach/PEG but also other options such as mech. assist devices), if and only if these therapies align with the defined goals of care.
I got tired of opening a dozen PDFs to find the ECMO pressure/flow curve I need.
So I made an app!
Choose the cannula/size and you can see the max flow for a given pressure drop. Or compare multiple different cannula.
Lmk what ya’ll think. Useful? What’s it need?
onepagericu.com/ecmo-calcula...
Recently listened to this:
soundphysicians.com/podcast-epis...
Has some good pearls and pitfalls and some resources in the shownotes.
Let us start 2025 in a positive mood: here are 10 methods things researchers can worry *less* about in 2025
📌
ICYMI #emimcc
This was a fun study leveraging social media to demonstrate the high prevalence in Impella malrotation among cases shared on old Twitter.
If it's malrotated, but it works well, without suction alarms or other problems, do you change it? #cccsky #cardiosky #emimcc
www.pcronline.com/News/Whats-n...
Do you/does anyone know if there are data repositories with patient data, timepoints and vanco levels as well as reference clearence (maybe from observational studies)?
We could then use that to 1) validate and 2) develop new models.
#emimcc
I plan to do a thread on the paper/topic soon. This project has kept me busy over the last two years and it has been a pleasure working alongside an awesome steering committee and Delphi panel. 🙏
Fresh off the press: COSMOGI 🗞️🗞️🔥🔥
What variables should we use to daily monitor #gastrointestinal function in #criticalcare?
We have developed a core outcome set and have defined 13 variables for daily GI assessment. Published today in Critical Care:
ccforum.biomedcentral.com/articles/10....
#MedSky #EMIMCC #IDsky #cardiosky
@pulmcrit.bsky.social
What is the culture at your hospital for potassium replacement?
At most hospitals I'm at it seems to be a culture of replace to K 4.0 and the individual doctor makes the call.
This paper confirms my bias...
jamanetwork.com/journals/jam...
Results of the #SAHARAtrial released after #CCRdownunder. A lot to discuss…
www.nejm.org/doi/full/10....
#neurocriticalcare
No, this was just a (very simple) approximation; imagine a trial that onlynlooked atbthis group and enrolled that number of patients. As the groups are exclusive, this was a first step to get a feeling of how much of a difference there really is…
The immunocompromised group was stopped for futility. I think that these groups are not powered enough to draw any conclusion and the difference is just statistical noise. Early intubation may be warranted in these patients who can deteriorate rapidly, also for early diagnosis via bronch/lavage.
I agree, for cardiogenic NIPPV treats the not only the lungs but also the heart; this is why the results were suprising to me and I struggle with interpretation.
Awesome and interesting work by the late Luciano Gattinoni and colleagues.
#emimcc
CVP has the same function: it is the intersection of RV function curve and venous return, so it tells you how well the RV handles the VR and if there is RV dysfunction for that given state. It is no measure of volume status or responsiveness (but probably tolerance, as is VEXUS).